Blue March: Pierre Fabre supports colorectal cancer awareness month
Puma and CANBridge cancel licensing deal for $20m
Fight against cancer : our therapeutic responses | Pierre Fabre
Pierre Fabre étend sa collaboration avec Puma Biotechnology
Puma Biotech Expands Pierre Fabre License to Add Countries
Pierre Fabre engagements | NERLYNX
Puma regains China rights to Nerlynx and amends deal with Fabre
THE FACES OF BREAST CANCER
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Pierre Fabre pens oncology pact with atomic energy spinout | Fierce Biotech
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
Pierre Fabre amends license agreement with Puma Biotechnology - European Biotechnology
Pierre Fabre & NERLYNX commercialisation | Nerlynx
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Pierre Fabre étend ses droits sur le Nerlynx de Puma Biotechnology
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotechnology | Evaluate
Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Bio: Sifting Through The Q4 Earnings Report (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | Business Wire
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Fight against cancer : our therapeutic responses | Pierre Fabre
